AMT-130 has been granted Breakthrough Therapy designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.

A Belgian study compared exercise performance before and after COVID-19 lockdown measures were swiftly implemented in the country among patients with preexisting pulmonary arterial hypertension (PAH).

A home-based strength training program does not improve dyspnea in patients with chronic obstructive lung disease (COPD), but it does improve some functional capacity and helps patients feel better, a ...

Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by ...

A Huntington’s gene therapy by UniQure has made waves after slowing disease progression by 75% in a mid-stage trial. During ...

1 Sport Injury Prevention Research Centre, Faculty of Kinesiology, University of Calgary, Calgary, Canada 2 Alberta Children’s Hospital Research Institute, University of Calgary, Calgary, Canada 3 ...

In old age, a tighter interlinkage between different domains of functional capacity may indicate a loss of system resilience. When functional capacity domains are tightly interconnected, a disruption ...

T opline data showed that an investigational gene therapy slowed Huntington's disease progression and met its primary endpoint in a pivotal trial, uniQure Biopharma announced Wednesday.